BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
Takeda’s Ninlaro falls short in first line multiple myelomaTakeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid Share XTakeda’s Ninlaro falls short in first line multiple myelomahttps://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/
BMS/AbbVie’s combo falls short in untreated multiple myeloma trialAdding Bristol-Myers Squibb/AbbVie’s Empliciti to Revlimid, developed by BMS’ recently acquired Celgene unit, does not improve survival in Share XBMS/AbbVie’s combo falls short in untreated multiple myeloma trialhttps://pharmaphorum.com/news/bms-abbvies-combo-falls-short-in-untreated-multiple-myeloma-trial/
Boehringer bags CHMP backing for Ofev in rare lung diseaseBoehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the Share XBoehringer bags CHMP backing for Ofev in rare lung diseasehttps://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapyNICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a Share XNICE backs Celgene’s Revlimid for chemo-free lymphoma therapyhttps://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
Boosted by Celgene’s cash, BMS bounces back after mega-mergerBristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year Share XBoosted by Celgene’s cash, BMS bounces back after mega-mergerhttps://pharmaphorum.com/news/bms/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
BMS files first drug from triple bet with Celgene shareholders with FDABristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” Share XBMS files first drug from triple bet with Celgene shareholders with FDAhttps://pharmaphorum.com/news/bms-files-first-drug-from-triple-bet-with-celgene-shareholders-with-fda/
